Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.22 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.